title: The potential economic value of a human norovirus vaccine for the United States.
abstract: Vaccines against human norovirus are currently under development. We developed a simulation model to determine their potential economic value. Vaccination prevented 100-6125 norovirus gastroenteritis cases per 10,000 vaccinees. Low vaccine cost (≤$50) garnered cost-savings and a more expensive vaccine led to costs per case averted comparable to other vaccines. In the US, vaccination could avert approximately 1.0-2.2 million cases (efficacy 50%, 12 month duration), costing an additional $400 million to $1.0 billion, but could save ≤$2.1 billion (48 month duration). Human norovirus vaccination can offer economic value while averting clinical outcomes, depending on price, efficacy, and protection duration.
authors.affiliation: Public Health Computational and Operations Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Bartsch
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Lopman
authors.forename: Aron J
authors.initials: AJ
authors.lastname: Hall
authors.forename: Umesh D
authors.initials: UD
authors.lastname: Parashar
authors.forename: Bruce Y
authors.initials: BY
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017250:Caliciviridae Infections / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D003198:Computer Simulation; D003362:Cost-Benefit Analysis; D005260:Female; D005759:Gastroenteritis / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D029322:Norovirus / Q000276:immunology* / Q000472:pathogenicity; D014481:United States / Q000453:epidemiology; D014765:Viral Vaccines / Q000191:economics* / Q000276:immunology*; D055815:Young Adult
chemical_list: D014765:Viral Vaccines